Executive summary United States Drug Patent 11,969,439 is directed to a parenteral L-cysteine dosing method (with optional amino-acid co-administration) that controls aluminum exposure via a highly specific formulation envelope: L-cysteine:aluminum ratio (35,000,000:1 down to 140,000:1 depending on claim level), low solution pH (1.0 to 2.5), substantially no visible particulates, and maximum aluminum dose (≤ 3 mcg/kg/day or 4–5 mcg/kg/day depending on dependent-claim scope, with 9/12/18-month manufacturing stability variants). Claim 8 and claim 16/24/30 anchor the method to TPN. The claim set is method-of-treatment centered on a defined composition and dosing regimen; competitive design-arounds will focus on breaking the ratio, pH, visible-particulate, and/or aluminum daily exposure limitations, or shifting to non-aluminum-compliant preparations.

What claims are in US Patent 11,969,439 and what do they cover?

Core claim architecture: method-of-treatment claims that require parenteral administration of a composition characterized by both composition parameters (L-cysteine, aluminum, carrier; pH; particulate; ratio) and exposure outcomes (≤ aluminum mcg/kg/day; ratio performance for a specified duration “from time of manufacture”).

Claim 1: What is the foundational independent scope?

Claim 1 requires, in combination:

A method of treating a subject with an adverse health condition responsive to L-cysteine.
Parenteral administration of a composition containing:
- L-cysteine (or pharmaceutically acceptable salts and/or hydrates),
- Aluminum,
- pharmaceutically acceptable carrier.
Ratio limitation: L-cysteine:aluminum = 35,000,000:1 to 140,000:1 for at least 6 months from manufacture.
Solution properties:
- pH 1.0 to 2.5
- substantially free of visually detectable particulate matter
Aluminum exposure ceiling: provides not more than 3 mcg/kg/day of aluminum.

Business consequence: the independent claim is not simply “low aluminum.” It is a coupled constraint: ratio + stability-from-manufacture duration + low pH + particulate-free while maintaining ≤3 mcg/kg/day aluminum dose during use.

Claims 2–4: How does the ratio range narrow by dependent claim?

These depend from claim 1 and narrow the ratio range to upper-aligned subranges while preserving the independent claim’s remaining limitations:

Claim 2: ratio 1,800,000:1 to 140,000:1
Claim 3: ratio 700,000:1 to 140,000:1
Claim 4: ratio 170,000:1 to 140,000:1

Interpretation for freedom-to-operate (FTO): any competing product/formulation must either stay outside these ratio bands or violate at least one other required element (pH, particulates, daily aluminum, or stability duration).

Claims 5–7: What is the optional amino-acid extension?

Claim 5 depends from claim 1 and adds:

The composition further includes one or more amino acids selected from:
- leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine, tryptophan, alanine, arginine, glycine, proline, serine, tyrosine
The composition provides not more than 5 mcg/kg/day of aluminum
The solution is still characterized by the independent claim’s ratio, pH, particulate, and L-cysteine/aluminum presence.

Claim 6 narrows the aluminum exposure to not more than 4 mcg/kg/day.

Claim 7 further narrows formulation composition by adding:

~15–40 mg L-cysteine per gram of the one or more amino acids.

Key nuance: the amino-acid dependent claims lift the aluminum exposure ceiling from the independent claim’s ≤3 mcg/kg/day to ≤5 mcg/kg/day (and then ≤4 mcg/kg/day for claim 6). This makes the dependent claim set relevant to TPN-like matrices where amino acids are present.

Claim 8: Is TPN explicitly claimed?

Yes. Claim 8 states the adverse condition is the need for total parenteral nutrition (TPN).

Implication: even if the adverse condition remains generic “responsive to L-cysteine,” claim 8 provides an explicit clinical use anchor for TPN.

How do claims 9–17 change the “for at least X months from manufacture” stability requirement?

Claims 9, 17, and 25 introduce the same essential formulation and dosing logic but require the ratio to hold for longer time windows.

Claim 9: at least 9 months

Like claim 1 but with:

Ratio 35,000,000:1 to 140,000:1 for at least 9 months from time of manufacture
Same pH 1.0 to 2.5
Same “substantially free of visually detectable particulate matter”
Same ≤3 mcg/kg/day aluminum cap
Same “responsive to L-cysteine” adverse condition framing

Claims 10–12 narrow the ratio bands within that framework:

Claim 10: 1,800,000:1 to 140,000:1
Claim 11: 700,000:1 to 140,000:1
Claim 12: 170,000:1 to 140,000:1

Claims 13–15: amino acids in the 9-month stability version

Claim 13 adds amino-acid selection and ≤5 mcg/kg/day aluminum.

Claim 14 tightens to ≤4 mcg/kg/day.

Claim 15 adds ~15–40 mg L-cysteine per gram amino acids.

Claim 16: TPN explicitly claimed in the 9-month family

Claim 16 makes the adverse condition TPN.

Do claims 17–24 add a 12-month stability requirement?

Claim 17: at least 12 months

This repeats claim 1’s formulation/dose structure with:

Ratio 35,000,000:1 to 140,000:1 for at least 12 months from manufacture
pH 1.0 to 2.5
no visible particulates
≤3 mcg/kg/day aluminum

Claims 18–20 narrow ratio bands:

Claim 18: 1,800,000:1 to 140,000:1
Claim 19: 700,000:1 to 140,000:1
Claim 20: 170,000:1 to 140,000:1

Claims 21–23: amino-acid dependent, 12-month version

Claim 21 adds amino acids and ≤5 mcg/kg/day.

Claim 22 tightens to ≤4 mcg/kg/day.

Claim 23 adds ~15–40 mg L-cysteine per gram amino acids.

Claim 24 ties the adverse condition to TPN.

Do claims 25–30 add an 18-month stability requirement?

Claim 25: at least 18 months

This repeats the full formulation constraints with the ratio requirement lasting:

Ratio 35,000,000:1 to 140,000:1 for at least 18 months from manufacture
pH 1.0 to 2.5
substantially free of visually detectable particulates
≤3 mcg/kg/day aluminum

Claims 26–27 narrow ratio bands:

Claim 26: 1,800,000:1 to 140,000:1
Claim 27: 170,000:1 to 140,000:1

Claims 28–29: amino-acid dependent, 18-month version

Claim 28 adds amino acids and ≤5 mcg/kg/day aluminum.
Claim 29 adds ~15–40 mg L-cysteine per gram amino acids.

Claim 30 explicitly states the adverse condition is TPN.

What “knobs” define infringement risk under US 11,969,439?

A competitor’s FTO risk turns on satisfying all elements tied together in each asserted claim. The main “knobs” are:

Parenteral administration method for an adverse condition responsive to L-cysteine
- and explicitly TPN for dependent claim(s) 8/16/24/30.
Composition contains aluminum plus L-cysteine (or salts/hydrates) and a pharmaceutically acceptable carrier.
Ratio envelope: L-cysteine:aluminum between 35,000,000:1 and 140,000:1, with nested dependent subranges.
Ratio stability requirement: ratio must hold for at least 6 / 9 / 12 / 18 months from time of manufacture, depending on the claim family being asserted.
Solution pH: 1.0 to 2.5.
Particulate condition: “substantially free of visually detectable particulate matter.”
Aluminum exposure ceiling:
- ≤3 mcg/kg/day in independent claim base families (1, 9, 17, 25)
- ≤5 mcg/kg/day (claim 5/13/21/28) and ≤4 mcg/kg/day (claim 6/14/22) when amino acids are present.
TPN linkage: explicit in claim 8/16/24/30.

Design-around pattern: a product can avoid infringement by modifying formulation or clinical use to fail one required element, most practically:

alter pH outside 1.0–2.5,
use a different aluminum content/exposure such that the dosing is above the claim ceilings or the ratio does not fall within the required window,
shift stability characteristics so the ratio target is not maintained for the required months “from manufacture,”
incorporate formulation attributes so it is not “substantially free of visually detectable particulate matter” as characterized, though this is usually a quality risk rather than a deliberate design-around,
or avoid the TPN treatment context if only the TPN-dependent claims are asserted (while still risking the broader “responsive to L-cysteine” independent claims).

What is the likely technological purpose behind the claims?

The claims operationalize a control strategy for aluminum exposure in L-cysteine-containing parenteral solutions, with strict constraints that imply:

aluminum species and/or complexation is managed to keep aluminum dose low relative to cysteine,
formulation is maintained at very acidic pH (1.0–2.5) to manage aluminum solubility/chemistry and/or reduce precipitation and particulates,
and formulation is engineered to hold the L-cysteine-to-aluminum ratio over long periods from manufacture, supporting long shelf-life and/or extended stability in clinical readiness.

The presence of TPN-specific dependents indicates the intended setting is intravenous nutrition mixtures where amino acids are present and aluminum control is clinically material.

How to assess claim strength vs. typical invalidity and enforceability attack surfaces?

Based on the claim language provided, the typical battlegrounds in US litigation would be:

Anticipation/obviousness: prior art must disclose the same combination of (i) parenteral L-cysteine + aluminum, (ii) the specific ratio window, (iii) pH and particulate-free conditions, and (iv) the aluminum daily exposure ceiling, plus (v) the “for at least X months from manufacture” stability characteristic.
Enablement/definiteness: “substantially free of visually detectable particulate matter” and the ratio “for at least X months from manufacture” invite questions on measurement methods and boundaries.
Written description: the detailed parameter constraints raise the bar for the specification’s support of each numeric limitation.

From a practical standpoint, the numeric specificity increases the difficulty for broad prior art to map cleanly, but it also increases sensitivity to prior art that may show similar low-aluminum parenteral strategies using pH control and known stability frameworks.

What does the patent landscape likely look like around aluminum exposure in parenteral nutrition and cysteine?

Even without asserting other specific US patent numbers in this response, the landscape around this claim set typically clusters into:

Aluminum impurity control in parenterals (formulation and manufacturing controls).
Chelation/complexation strategies with amino acids, acids, or cysteine-related chemistry.
Acidified L-cysteine formulations intended for solubility and stability.
TPN solution compatibility for long-term clinical use and shelf-life.

US 11,969,439 is best characterized as a composition-constrained method-of-treatment aimed at TPN-relevant administration where aluminum exposure is capped by formulation design.

What freedom-to-operate (FTO) scenarios matter for competitors?

Scenario A: generic or follow-on L-cysteine parenteral product

Key risk: if the competitor’s product uses aluminum and maintains:

pH 1.0–2.5,
the ratio window for the same stability duration,
and delivers ≤3 mcg/kg/day aluminum in the same TPN-like administration context, it may fall into the independent claim families (and even more so the amino-acid dependent families).

Scenario B: cysteine used as part of a broader TPN amino-acid formulation

Risk increases if:

aluminum-containing cysteine solution is combined in TPN,
amino acids listed in claims are present,
and aluminum exposure remains within the dependent claim ceilings (≤5 or ≤4 mcg/kg/day) with the cysteine-to-amino-acid mass ratio ~15–40 mg/g.

Scenario C: products that avoid aluminum altogether

If a competitor designs out aluminum such that the formulation does not meet the required “composition comprising aluminum” element or cannot satisfy the ratio constraints, it can avoid the claims as written.

Key tables: claim parameters and quantitative limits

Table 1. Independent-method quantitative limits

Claim family	Ratio (L-cys : Al)	Ratio duration from manufacture	pH range	Visual particulates	Aluminum exposure cap
Claim 1	35,000,000:1 to 140,000:1	≥ 6 months	1.0 to 2.5	Substantially free of visually detectable particulates	≤ 3 mcg/kg/day
Claim 9	35,000,000:1 to 140,000:1	≥ 9 months	1.0 to 2.5	Same	≤ 3 mcg/kg/day
Claim 17	35,000,000:1 to 140,000:1	≥ 12 months	1.0 to 2.5	Same	≤ 3 mcg/kg/day
Claim 25	35,000,000:1 to 140,000:1	≥ 18 months	1.0 to 2.5	Same	≤ 3 mcg/kg/day

Table 2. Dependent claim extensions with amino acids

Dependent claims	Amino-acid set	L-cys-to-amino-acid ratio	Aluminum exposure cap
Claims 5, 13, 21, 28	Leu, Ile, Lys, Val, Phe, His, Thr, Met, Trp, Ala, Arg, Gly, Pro, Ser, Tyr	(Only in claims 7/15/23/29) ~15–40 mg/g	≤ 5 mcg/kg/day
Claims 6, 14, 22	Same amino-acid concept	N/A	≤ 4 mcg/kg/day
Claims 7, 15, 23, 29	Same amino-acid concept	~15–40 mg L-cys per gram amino acids	Inherited from their parent cap (≤5 or ≤4 depending on chain)

Table 3. TPN explicit dependents

Claim	Adverse condition
Claim 8	Need for total parenteral nutrition (TPN)
Claim 16	Need for TPN
Claim 24	Need for TPN
Claim 30	Need for TPN

What is the practical claim-comparison across the 6/9/12/18-month variants?

The independent structure repeats; the only major structural change is the stability-from-manufacture duration attached to the ratio limitation:

6 months (claim 1),
9 months (claim 9),
12 months (claim 17),
18 months (claim 25).

From an infringement standpoint, if an accused product can be shown to satisfy the stricter long-duration stability versions, it necessarily fits the shorter ones on the ratio-stability element, assuming the other elements match. Litigation will therefore often center on the accused product’s real stability data on the relevant shelf-time metric “from time of manufacture.”

Key Takeaways

US 11,969,439 is a quantitatively tight method-of-treatment for L-cysteine responsive indications, with explicit TPN dependents.
The claim set requires a coupled formulation envelope: L-cysteine + aluminum + low pH (1.0–2.5) + minimal visible particulates + a specified L-cysteine:aluminum ratio maintained for 6/9/12/18 months from manufacture.
Aluminum exposure is capped at ≤3 mcg/kg/day in base families and ≤5 or ≤4 mcg/kg/day in amino-acid dependent families, with an added ~15–40 mg L-cysteine per gram amino acids condition in specific dependents.
Competitive FTO risk is driven by the accused product’s ability to meet all of: ratio, stability duration, pH, particulate condition, and the daily aluminum ceiling in the relevant administration context.

FAQs

1) What would most easily break infringement for L-cysteine plus aluminum parenterals under US 11,969,439?
Failing any required numeric element, most practically the L-cysteine:aluminum ratio, the pH range, the ≤3/≤5/≤4 mcg/kg/day aluminum exposure, or the ratio stability for 6/9/12/18 months from manufacture.

2) Does the patent cover cysteine formulations without amino acids?
Yes. The base independent families (1/9/17/25) cover the method without requiring the listed amino-acid set; amino acids appear only in dependent claim extensions (5/6/7 etc.).

3) Is TPN an essential element for all claims?
No. TPN is explicit only in dependent claims 8/16/24/30. Independent claims still require “an adverse health condition responsive to L-cysteine,” which can be broader than TPN.

4) How do the 6-, 9-, 12-, and 18-month claim versions differ?
They differ on how long the L-cysteine:aluminum ratio must be maintained from time of manufacture: ≥6, ≥9, ≥12, or ≥18 months, while preserving the other formulation and exposure constraints.

5) What matters most for aluminum exposure proof in litigation of these claims?
Demonstrating the accused dosing regimen’s aluminum delivered per kg per day in the relevant administration, tied to the formulation parameters (ratio, pH, and stability duration) that the claims require.

References

United States Patent 11,969,439.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exela Pharma	ELCYS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	210660-001	Apr 16, 2019		RX	Yes	Yes	11,969,439	⤷ Start Trial				METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 11,969,439

Which drugs does patent 11,969,439 protect, and when does it expire?

Summary for Patent: 11,969,439